Extended Data Fig. 5: Induction of tetanus helper peptide responses after treatment.
From: Atezolizumab plus personalized neoantigen vaccination in urothelial cancer: a phase 1 trial
a, IFNγ spot forming cells (SFCs)/million plated PBMCs at each timepoint after stimulation with tetanus helper peptide. The plot depicts the mean with standard error of the mean. N = 9 for Pre, N = 9 for Prime, N = 7 for Boost, N = 6 for Post. Statistical significance was determined by Kruskal-Wallis test corrected for multiple comparisons using Dunn’s test. Adjusted P = 0.0026 for Pre vs. Prime, adjusted P = 0.0004 for Pre vs. Boost, adjusted P = 0.0085 for Pre vs. Post. b, Flow cytometry analysis of CD4+ (left) and CD8+(right) T cell response to tetanus helper peptide at each timepoint. Patients representative of each line are listed.
